Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies

van Hooff, Johannes P.;Alloway, Rita R.;Trunečka, Pavel;Mourad, Michel
(2011) Clinical Transplantation — Vol. 25, n° 1, p. E1-E12 (2011)

Files

vanHooff-2011-Four-yearexperience.pdf
  • Restricted Access
  • Adobe PDF
  • 417.28 KB
Request a copy

Details

Authors
  • van Hooff, Johannes P.
    Author
  • Alloway, Rita R.
    Author
  • Trunečka, Pavel
    Author
  • Mourad, MichelUCLouvain
    Author
Abstract
This study assessed the long-term effects of prolonged-release tacrolimus (Advagraf(®) [Tacrolimus QD]), which has been developed to provide similar efficacy and safety to twice-daily tacrolimus (Prograf(®) [Tacrolimus BID]) with the added benefit of once-daily dosing.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

van Hooff, J. P., Alloway, R. R., Trunečka, P., & Mourad, M. (2011). Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clinical Transplantation, 25(1), E1-E12. https://doi.org/10.1111/j.1399-0012.2010.01377.x (Original work published 2011)